Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Shire's juggling act

By licensing balsalazide from Salix Pharmaceuticals Ltd., Shire Pharmaceuticals Group plc now has two products to treat ulcerative colitis. SHP already owns U.S. rights to Pentasa as

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE